Skip to main content
. 2020 May 4;10(5):48. doi: 10.1038/s41408-020-0318-1

Fig. 3. Survival outcomes by NPM1 co-mutation and FLT3 allelic ratio.

Fig. 3

a, b Overall survival and relapse free survival in patients treated with TKI regardless of intensity of chemotherapy by NPM1 status within the FLT3 high allelic group. c, d Overall survival and relapse free survival in patients treated with TKI regardless of intensity of chemotherapy by NPM1 status within the FLT3 low allelic group.